Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 851 - 900 out of 131,777

Document Document Title
WO/2018/065529A1
Provided are novel crystalline forms of a spiro-compoundwhich acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8- methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are describ...  
WO/2018/067971A1
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.  
WO/2018/067579A1
Devices, systems and methods are provided for delivering coffee-derived volatiles to a user, particularly for the treatment of addiction. The coffee volatiles are selected and delivered by devices and systems which allow for concentrated...  
WO/2018/064738A1
The present invention relates to a composition comprising SEQ ID NO: 1 or 2 and one or more pharmaceutically acceptable carriers or diluents. The present invention further relates to the use of the composition as defined in claim 1 or SE...  
WO/2018/067879A1
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes ...  
WO/2018/066718A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : in which n, X, R1, R2, R3 and R4 are as defined in the specification, processes for their preparation, pharmaceutical compositions co...  
WO/2018/067102A1
The invention relates to medical chemistry, in particular to the use of 7-bromo-5-(o-chlorophenyl)-3-propoxy-l,2-dihydro-3H-l,4-benz odiazepin-2-one as a drug which inhibits neuropathic pain without the formation of defects in the gastri...  
WO/2018/059212A1
Provided are a series of compounds reducing SAICAR accumulation, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and ob...  
WO/2018/059531A1
A crystal form of an adenosine A2A receptor antagonist drug, tozadenant, and a preparation method and use thereof. The prepared tozadenant has crystal form CS1, can be used to prepare an adenosine A2A receptor antagonist drug formulation...  
WO/2018/060300A1
The present invention relates to a compound of formula (I), wherein R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy or lower alkoxy substituted by halogen; R may be the same or different, if n = 2 o...  
WO/2018/058296A1
Hydrochloride, phosphate, maleate, citrate and tartrate of TTP488 and crystal forms, preparation methods for the salts of the TTP488 and the crystal forms thereof, pharmaceutical compositions thereof, and uses thereof in the preparation ...  
WO/2018/064377A1
Systems and methods are provided herein for transdermal delivery of an opioid. The opioids can be delivered in a decreasing dose (dose-tapering) manner to minimize withdrawal symptoms and abuse. The systems are also designed to limit a p...  
WO/2018/064649A1
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...  
WO/2018/059213A1
Provided are compounds interfering with SAICAR synthesis, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain co...  
WO/2018/060396A1
A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid and...  
WO/2018/060742A1
The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30)...  
WO/2018/059420A1
The present invention relates to a crystal form of a Sigma-1 receptor antagonist drug, preparation method therefor and use thereof. The crystal form of E52862 hydrochloride salt provided in the present invention, named crystal form H, ca...  
WO/2018/060395A1
A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a ...  
WO/2018/064135A1
The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these c...  
WO/2018/058984A1
Disclosed are a health-promoting beverage suitable for insomnia sufferers and a manufacturing method thereof. The beverage comprises the following components provided in respective mass fractions: 0.05-0.3 parts of Asian ginseng extract;...  
WO/2018/059214A1
Provided are compounds affecting SAICAR synthesis, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds...  
WO/2018/060732A2
Functional analogs of fenfluramine are provided. The subject fenfluramine functional analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subjec...  
WO/2018/064498A1
The disclosure provides methods to prevent, inhibit or treat one or more symptoms associated with epilepsy or encephalopathies in a mammal, comprising: administering to the mammal, e.g., a composition having one of more of compounds of f...  
WO/2018/064436A1
A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 week...  
WO/2018/059241A1
Disclosed are an extract with a detoxification pharmaceutical effect and a preparation method therefor. An effective component of the extract has the following chemical structural characteristics: a cholestenol compound with hydroxyl (OH...  
WO/2018/059211A1
Provided are applications of spermine and derivatives thereof. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds capab...  
WO/2018/063955A1
The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from (II), (III), (IV), and (V...  
WO/2018/059395A1
Provided are compounds weakening SAICAR synthase activity, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain c...  
WO/2018/059216A1
Disclosed are compounds reducing SAICAR synthase activity, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain c...  
WO/2018/059215A1
Disclosed are compounds reducing SAICAR accumulation, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compou...  
WO/2018/059429A1
The invention relates to non-solvated crystals A, B and C of N-(2-aminophenyl)-6-(7-methoxyquinoline-4-oxy)-1-naphthamide and preparation methods thereof. The invention also relates to pharmaceutical compositions containing the crystals...  
WO/2018/060732A3
Functional analogs of fenfluramine are provided. The subject fenfluramine functional analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subjec...  
WO/2018/059396A1
Provided are compounds reducing SAICAR accumulation, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compoun...  
WO/2018/059739A1
The present invention describes a new method and new combination products for the therapy of neurological and other conditions which respond to dopaminergic therapies and especially to L-DOPA (L-Dihydroxy-Phenylalanine) based on the use ...  
WO/2018/056905A1
The present invention relates to co-crystals comprising the Nuclear receptor related 1 protein-ligand binding domain (Nurr1-LBD) and a cyclopentenone prostaglandin. Also provided are methods of identifying or designing Nurr1-modulating l...  
WO/2018/057989A1
The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurologic...  
WO/2018/058098A1
The present invention provides methods for treating Alzheimer's Disease, or preventing synaptic death associated with Alzheimer's Disease by administering a Pyk2 inhibitor. In certain embodiments, the Pyk2 inhibitor is specific for Pyk2....  
WO/2018/055574A1
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a 5 mono...  
WO/2018/056123A1
Disclosed is a composition containing enzyme-decomposed royal jelly granules and zein, the composition serving as a food item, a pharmaceutical item, or a quasi-drug.  
WO/2018/055096A1
This invention relates to new inhibitors of MAO-Bwith the general formula I, where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the form of pharmaceutica...  
WO/2018/057484A1
Review daily docket and provide responses for clearance; including reviewing records and files as needed; review docketing related confirmation emails of foreign agent correspondence for accuracy; forwarding emails to attorney/secretary ...  
WO/2018/057973A4
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments describ...  
WO/2018/056453A1
The present invention provides a compound represented by formula (I) in which an indole ring or a pyrrolo[2,3-b]pyridine ring and a pyrazolopyridine skeleton are bonded using a substituent, or a salt of the compound; solvates thereof; an...  
WO/2018/056442A1
The present invention provides a composition and a method for efficiently delivering a nucleic acid agent to the central nervous system and/or the retina and bringing about antisense effects. Provided is a composition for reducing the ex...  
WO/2018/053618A1
There is described herein a method for culturing mesenchymal stromal cells (MSCs) comprising: a) providing a population comprising mesenchymal stromal cells; and b) enhancing the population under conditions that allow the MSCs to loosely...  
WO/2018/057514A1
Methods for increasing reelin (RELN) levels in the brain of a subject in need thereof, as well as compositions for use in such methods, are provided. In addition, methods and compositions are described herein which may be used in the tre...  
WO/2018/056412A1
The purpose of the present invention is to provide a Schwann cell differentiation promoter, a peripheral nerve regeneration promoter, or the like that contains an extract from inflamed tissue inoculated with vaccinia virus. The present i...  
WO/2018/057973A1
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments describ...  
WO/2018/056854A1
This invention relates to: (a) compounds of formula (I) (with R1 to R5, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical compos...  
WO/2018/057576A1
Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula I, which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-s...  

Matches 851 - 900 out of 131,777